Hoth Therapeutics Net Worth
Hoth Therapeutics Net Worth Breakdown | HOTH |
Hoth Therapeutics Net Worth Analysis
Hoth Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Hoth Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Hoth Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Hoth Therapeutics' net worth analysis. One common approach is to calculate Hoth Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Hoth Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Hoth Therapeutics' net worth. This approach calculates the present value of Hoth Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Hoth Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Hoth Therapeutics' net worth. This involves comparing Hoth Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Hoth Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Hoth Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Hoth Therapeutics' net worth research are outlined below:
| Hoth Therapeutics generated a negative expected return over the last 90 days | |
| Hoth Therapeutics has some characteristics of a very speculative penny stock | |
| Hoth Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (7.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hoth Therapeutics currently holds about 11.62 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Hoth Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Poor Kevin Jess of 750000 shares of Hoth Therapeutics subject to Rule 16b-3 |
Hoth Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Hoth Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Hoth Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Hoth Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Hoth Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Hoth Therapeutics backward and forwards among themselves. Hoth Therapeutics' institutional investor refers to the entity that pools money to purchase Hoth Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Qube Research & Technologies | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Hrt Financial Llc | 2024-09-30 | 121.9 K | Geode Capital Management, Llc | 2024-09-30 | 82.9 K | Ubs Group Ag | 2024-09-30 | 56.5 K | Vanguard Group Inc | 2024-09-30 | 38.8 K | Two Sigma Securities, Llc | 2024-09-30 | 18.6 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 10.3 K | Tower Research Capital Llc | 2024-09-30 | 4.5 K | Royal Bank Of Canada | 2024-09-30 | 240 | Bank Of America Corp | 2024-09-30 | 56.0 |
Follow Hoth Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.85 M.Market Cap |
|
Project Hoth Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.87) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.82) | (0.87) | |
| Return On Equity | (0.89) | (0.93) |
When accessing Hoth Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Hoth Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Hoth Therapeutics' profitability and make more informed investment decisions.
Evaluate Hoth Therapeutics' management efficiency
Hoth Therapeutics has return on total asset (ROA) of (0.4616) % which means that it has lost $0.4616 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8341) %, meaning that it created substantial loss on money invested by shareholders. Hoth Therapeutics' management efficiency ratios could be used to measure how well Hoth Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.87. The current Return On Capital Employed is estimated to decrease to -0.91. The Hoth Therapeutics' current Net Tangible Assets is estimated to increase to about 11.9 M, while Total Assets are projected to decrease to under 5.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.59 | 4.27 | |
| Tangible Book Value Per Share | 2.59 | 4.27 | |
| Enterprise Value Over EBITDA | 25.43 | 26.71 | |
| Price Book Value Ratio | 0.56 | 0.53 | |
| Enterprise Value Multiple | 25.43 | 26.71 | |
| Price Fair Value | 0.56 | 0.53 | |
| Enterprise Value | -4.3 M | -4.1 M |
Understanding the operational decisions made by Hoth Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Return On Equity (0.83) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hoth Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hoth Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hoth Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Poor Kevin Jess over two weeks ago Acquisition by Poor Kevin Jess of 750000 shares of Hoth Therapeutics subject to Rule 16b-3 | ||
Linsley Wayne over three months ago Acquisition by Linsley Wayne of 25000 shares of Hoth Therapeutics at 0.7548 subject to Rule 16b-3 | ||
Sarnoff David over three months ago Acquisition by Sarnoff David of 33000 shares of Hoth Therapeutics at 2.11 subject to Rule 16b-3 | ||
Robb Knie over three months ago Acquisition by Robb Knie of 225000 shares of Hoth Therapeutics at 2.11 subject to Rule 16b-3 | ||
Hayes Anthony over three months ago Insider Trading | ||
Sarnoff David over six months ago Acquisition by Sarnoff David of 7500 shares of Hoth Therapeutics at 2.59 subject to Rule 16b-3 | ||
Robb Knie over six months ago Acquisition by Robb Knie of 225000 shares of Hoth Therapeutics subject to Rule 16b-3 | ||
Robb Knie over a year ago Acquisition by Robb Knie of 40000 shares of Hoth Therapeutics subject to Rule 16b-3 |
Hoth Therapeutics Earnings per Share Projection vs Actual
Hoth Therapeutics Corporate Management
| Jane Springer | VP Operations | Profile | |
| Hayley Springer | Executive Operations | Profile | |
| Stefanie Johns | Chief Officer | Profile | |
| David Briones | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Return On Assets (0.46) | Return On Equity (0.83) |
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.